A study of vistusertib in combination with selumetinib in patients with advanced cancers: TORCMEK phase Ib results.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.2548
Abstract: 2548Background: PI3K/mTOR and MAPK pathways are aberrantly activated in many tumours and interact to promote tumour growth and therapeutic resistance. Activity of single pathway inhibition is limit... read more here.
Keywords: study vistusertib; vistusertib combination; selumetinib patients; advanced cancers ... See more keywords